Filing Flows › Zenas BioPharma (ZBIO) › Q3 2026 › vs Q2 2026
Zenas BioPharma (ZBIO) Q3 2026 vs Q2 2026 (quarter over quarter)
Zenas BioPharma's revenue rose $9.0M (+900%) from $1.0M in Q2 2026 to $10.0M in Q3 2026.
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $10.0M | $1.0M | $9.0M | +900% |
| Net loss | $109M | $111M | −$2.5M | -2% |
| Costs & expenses | $119M | $112M | $6.5M | +6% |
| Operating costs | $113M | $109M | $4.8M | +4% |
| Interest & other, net | $5.5M | $3.7M | $1.8M | +48% |
| Income tax | $49K | $114K | −$65K | -57% |
| Research & development | $58.5M | $62.9M | −$4.4M | -7% |
| General & admin | $27.4M | $15.7M | $11.7M | +74% |
| Other operating costs | $27.5M | $30.0M | −$2.5M | -8% |
| Operating cash sources | $109M | $111M | −$2.5M | -2% |
| Depreciation | $4K | $4K | $0 | 0% |
| Share-based compensation | $17.3M | $8.6M | $8.7M | +100% |
| Working capital & other | $33.7M | $45.6M | −$11.9M | -26% |
| Cash used in operations | $58.0M | $57.2M | $747K | +1% |
| Net loss absorbed | $109M | $111M | −$2.5M | -2% |
Questions
How much did Zenas BioPharma's revenue grow quarter over quarter in Q3 2026?
Zenas BioPharma's revenue rose $9.0M (+900%) from $1.0M in Q2 2026 to $10.0M in Q3 2026.